Co-occurring genomic alterations in non-small-cell lung cancer biology and therapy
By A Mystery Man Writer
Description
Cells, Free Full-Text
Co-mutations in tumor immune microenvironment and immunotherapy
Immunogenomic profiling of lung adenocarcinoma reveals high-grade growth patterns are associated with an immunogenic tumor microenvironment
Genomic alterations in intrahepatic cholangiocarcinoma
Co-occurring genomic alterations in non-small-cell lung cancer biology and therapy. - Abstract - Europe PMC
Fully accessible fitness landscape of oncogene-negative lung adenocarcinoma
Frontiers The landscape of actionable genomic alterations in lung adenocarcinomas in India
Landscape of EGFR mutations in lung adenocarcinoma: a single institute experience with comparison of PANAMutyper testing and targeted next-generation sequencing
Co-occurring genomic alterations and immunotherapy efficacy in NSCLC
Clinicopathologic features, concurrent genomic alterations, and clinical outcomes of patients with KRAS G12D mutations in resected lung adenocarcinoma - ScienceDirect
Genomic alterations in biliary tract cancer predict prognosis and immunotherapy outcomes
Comprehensive molecular profiling of lung adenocarcinoma
The study of primary and acquired resistance to first-line osimertinib to improve the outcome of EGFR-mutated advanced Non-small cell lung cancer patients: the challenge is open for new therapeutic strategies - ScienceDirect
Frontiers Co-Occurring Alterations of ERBB2 Exon 20 Insertion in Non-Small Cell Lung Cancer (NSCLC) and the Potential Indicator of Response to Afatinib
from
per adult (price varies by group size)